“Durability of DLQI Improvements Among Patients With Moderate to Severe Plaque Psoriasis Treated With Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s80. Accessed April 29, 2026. https://skin.dermsquared.com/skin/article/view/1113.